33581-95-2Relevant articles and documents
Strongly UV absorbing bifunctional azoalkanes
Engel, Paul S.,Wu, Huifang,Smith, William B.
, p. 3145 - 3148 (2001)
(Figure Presented) Two new anthracene-containing azoalkanes (1 and 2) absorb UV light 600 times more strongly than simple azoalkanes. Intramolecular energy transfer from excited singlet anthracene to the azo group is nearly complete, but despite the close proximity of the two chromophores, 1 and 2 continue to exhibit anthracene fluorescence. Thermolysis of these compounds in the presence of monomers affords fluorescent labeled polymers. Compounds 1 and 2 are the first azoalkanes to undergo induced decomposition in solution.
Synthesis of α-alkylated γ-butyrolactones with concomitant anhydride kinetic resolution using a sulfamide-based catalyst
Claveau, Romain,Twamley, Brendan,Connon, Stephen J.
supporting information, p. 7574 - 7578 (2018/11/02)
The Kinetic Resolution (KR) of α-alkylated enolisable disubstituted anhydrides has been shown to be possible for the first time. In the presence of an ad hoc designed novel class of bifunctional sulfamide organocatalyst, a regio-, diastereo- and enantioselective cycloaddition reaction between the enolisable anhydride and benzaldehydes provides densely functionalised γ-butyrolactones in one pot (up to 19:1 dr, 94% ee) with control over three contiguous stereocentres. The concomitant resolution of the starting material anhydride, provides access to a range of chiral succinate derivatives with selectivity factors up to S? = 10.5.
PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
-
Page/Page column 68-69, (2012/11/06)
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.